Vertex Pharmaceuticals has reported positive data from Phase 1 and Phase 2 trials of three different triple combination regimens in cystic fibrosis (CF) patients who have one F508del mutation and one minimal function mutation (F508del/Min).
PureTech Health has presented data for product candidate ALV-107 showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose (ALV-107 16 mg/kg, conventional lidocaine 16 mg/kg), in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
Elite Pharmaceuticals has reported topline results from a pivotal bioequivalence fed study for SequestOx.
Alnylam Pharmaceuticals and Sanofi Genzyme have commenced Atlas Phase 3 clinical program for hemophilia treatment, fitusiran.
Entasis Therapeutics and Global Antibiotic Research and Development Partnership (GARDP) will initiate pivotal trials of oral antibiotic zoliflodacin (ETX0914) being developed to treat drug-resistant gonorrhea.
Prothena has reported that the first patient has been enrolled in PASADENA, a global Phase 2 study of PRX002/RG7935 in patients with early Parkinson's disease.
Zealand Pharma has started a multinational Phase 3 clinical trial of dasiglucagon in four countries (Austria, Germany, Canada and the US).
Daiichi Sankyo's pain drug mirogabalin has showed mixed results in phase 3 global clinical development program.
bluebird bio has released topline interim data from the initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating its investigational gene therapy Lenti-D in under-18 boys with cerebral adrenoleukodystrophy (CALD).
Roche’s haemophilia A drug emicizumab has showed a significant effect in the phase III Haven 1 and Haven 2 studies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.